About Vitiligo Therapeutics
Vitiligo is the depigmentation of the skin cause by the death or malfunctioning of the melanocytes, which are responsible for the color of the skin. It occurs as patches on the skin and could also affect the hair and the inside of the mouth.
Technavio’s analysts forecast the Global Vitiligo Therapeutics Market to grow at a CAGR of 4.41% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the vitiligo therapeutics market. To calculate the market size, the report considers the revenue generated from the retail sales of all approved medicines, generic medicines, and off-label drugs used in the treatment of vitiligo across the globe.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, vitiligo therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Astellas Pharma
• Bausch Health
• Baxter
• Mallinckrodt
• Puneet Laboratories
Market driver
• Rising importance of aesthetic appeal
• For a full, detailed list, view our report
Market challenge
• Poor patient adherence
• For a full, detailed list, view our report
Market trend
• Growing disposable income in emerging countries
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: DISEASE OVERVIEW
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE
PART 09: MARKET SEGMENTATION BY ROA
• Segmentation by RoA
• Comparison by RoA
• Topical – Market size and forecast 2017-2022
• Oral – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by RoA
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Americas – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Astellas Pharma
• Bausch Health
• Baxter
• Mallinckrodt
• Puneet Laboratories
PART 17: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global vitiligo therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global vitiligo therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global vitiligo therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials
Exhibit 20: Global vitiligo therapeutics market segmentation by RoA
Exhibit 21: Global vitiligo therapeutics market segmentation by RoA – Market share 2017-2022 (%)
Exhibit 22: Comparison by RoA
Exhibit 23: Global vitiligo topical therapeutics market – Size and forecast 2017-2022 ($ mn)
Exhibit 24: Global vitiligo topical therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 25: Global vitiligo oral therapeutics market – Size and forecast 2017-2022 ($ mn)
Exhibit 26: Global vitiligo oral therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 27: Global vitiligo others therapeutics market – Size and forecast 2017-2022 ($ mn)
Exhibit 28: Global vitiligo others therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by RoA
Exhibit 30: Customer landscape
Exhibit 31: Global vitiligo therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Global vitiligo therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: Global vitiligo therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Global vitiligo therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: Global vitiligo therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 37: Global vitiligo therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: Global vitiligo therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Economic snapshot of India and China
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Astellas Pharma – Overview
Exhibit 48: Astellas Pharma – Business segments
Exhibit 49: Astellas Pharma – Organizational developments
Exhibit 50: Astellas Pharma – Geographic focus
Exhibit 51: Astellas Pharma – Segment focus
Exhibit 52: Astellas Pharma – Key offerings
Exhibit 53: Astellas Pharma – Key customers
Exhibit 54: Bausch Health – Overview
Exhibit 55: Bausch Health – Business segments
Exhibit 56: Bausch Health – Organizational developments
Exhibit 57: Bausch Health – Geographic focus
Exhibit 58: Bausch Health – Segment focus
Exhibit 59: Bausch Health – Key offerings
Exhibit 60: Bausch Health – Key customers
Exhibit 61: Baxter – Overview
Exhibit 62: Baxter – Business segments
Exhibit 63: Baxter – Organizational developments
Exhibit 64: Baxter – Geographic focus
Exhibit 65: Baxter – Segment focus
Exhibit 66: Baxter – Key offerings
Exhibit 67: Baxter – Key customers
Exhibit 68: Mallinckrodt – Overview
Exhibit 69: Mallinckrodt – Business segments
Exhibit 70: Mallinckrodt – Organizational developments
Exhibit 71: Mallinckrodt – Geographic focus
Exhibit 72: Mallinckrodt – Segment focus
Exhibit 73: Mallinckrodt – Key offerings
Exhibit 74: Mallinckrodt – Key customers
Exhibit 75: Puneet Laboratories – Overview
Exhibit 76: Puneet Laboratories – Business segments
Exhibit 77: Puneet Laboratories – Organizational developments
Exhibit 78: Puneet Laboratories – Geographic focus
Exhibit 79: Puneet Laboratories – Segment focus
Exhibit 80: Puneet Laboratories – Key offerings
Exhibit 81: Puneet Laboratories – Key customers
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: DISEASE OVERVIEW
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE
PART 09: MARKET SEGMENTATION BY ROA
• Segmentation by RoA
• Comparison by RoA
• Topical – Market size and forecast 2017-2022
• Oral – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by RoA
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Americas – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Astellas Pharma
• Bausch Health
• Baxter
• Mallinckrodt
• Puneet Laboratories
PART 17: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global vitiligo therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global vitiligo therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global vitiligo therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials
Exhibit 20: Global vitiligo therapeutics market segmentation by RoA
Exhibit 21: Global vitiligo therapeutics market segmentation by RoA – Market share 2017-2022 (%)
Exhibit 22: Comparison by RoA
Exhibit 23: Global vitiligo topical therapeutics market – Size and forecast 2017-2022 ($ mn)
Exhibit 24: Global vitiligo topical therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 25: Global vitiligo oral therapeutics market – Size and forecast 2017-2022 ($ mn)
Exhibit 26: Global vitiligo oral therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 27: Global vitiligo others therapeutics market – Size and forecast 2017-2022 ($ mn)
Exhibit 28: Global vitiligo others therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by RoA
Exhibit 30: Customer landscape
Exhibit 31: Global vitiligo therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Global vitiligo therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: Global vitiligo therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Global vitiligo therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: Global vitiligo therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 37: Global vitiligo therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: Global vitiligo therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Economic snapshot of India and China
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Astellas Pharma – Overview
Exhibit 48: Astellas Pharma – Business segments
Exhibit 49: Astellas Pharma – Organizational developments
Exhibit 50: Astellas Pharma – Geographic focus
Exhibit 51: Astellas Pharma – Segment focus
Exhibit 52: Astellas Pharma – Key offerings
Exhibit 53: Astellas Pharma – Key customers
Exhibit 54: Bausch Health – Overview
Exhibit 55: Bausch Health – Business segments
Exhibit 56: Bausch Health – Organizational developments
Exhibit 57: Bausch Health – Geographic focus
Exhibit 58: Bausch Health – Segment focus
Exhibit 59: Bausch Health – Key offerings
Exhibit 60: Bausch Health – Key customers
Exhibit 61: Baxter – Overview
Exhibit 62: Baxter – Business segments
Exhibit 63: Baxter – Organizational developments
Exhibit 64: Baxter – Geographic focus
Exhibit 65: Baxter – Segment focus
Exhibit 66: Baxter – Key offerings
Exhibit 67: Baxter – Key customers
Exhibit 68: Mallinckrodt – Overview
Exhibit 69: Mallinckrodt – Business segments
Exhibit 70: Mallinckrodt – Organizational developments
Exhibit 71: Mallinckrodt – Geographic focus
Exhibit 72: Mallinckrodt – Segment focus
Exhibit 73: Mallinckrodt – Key offerings
Exhibit 74: Mallinckrodt – Key customers
Exhibit 75: Puneet Laboratories – Overview
Exhibit 76: Puneet Laboratories – Business segments
Exhibit 77: Puneet Laboratories – Organizational developments
Exhibit 78: Puneet Laboratories – Geographic focus
Exhibit 79: Puneet Laboratories – Segment focus
Exhibit 80: Puneet Laboratories – Key offerings
Exhibit 81: Puneet Laboratories – Key customers
